Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
|ClinicalTrials.gov Identifier: NCT00489944|
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was: Recruiting
First Posted : June 21, 2007
Last Update Posted : January 10, 2014
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as tamoxifen and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with tamoxifen and cisplatin may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well giving sunitinib together with tamoxifen and cisplatin works in treating patients with high-risk ocular melanoma.
|Condition or disease||Intervention/treatment||Phase|
|Intraocular Melanoma||Drug: cisplatin Drug: sunitinib malate Drug: tamoxifen citrate Procedure: adjuvant therapy||Phase 2|
- Determine the effect of adjuvant sunitinib malate, tamoxifen citrate, and cisplatin on disease-free survival and overall survival of patients with high-risk ocular melanoma who have undergone primary therapy.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a pilot study.
Patients receive oral sunitinib malate once daily on days 1-21, oral tamoxifen citrate twice daily on days 1-7, and cisplatin IV on days 2 and 3. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 2 months for 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Official Title:||A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma|
|Study Start Date :||May 2007|
|Estimated Primary Completion Date :||December 2012|
- Disease-free survival
- Overall survival
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00489944
|United States, California|
|San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas||Recruiting|
|Encinitas, California, United States, 92024|
|Contact: Edward F. McClay, MD 760-452-3340 firstname.lastname@example.org|
|Principal Investigator:||Edward F. McClay, MD||San Diego Pacific Oncology & Hematology Associates|